MA-WATERS-CORPORATION
12.1.2022 15:12:07 CET | Business Wire | Press release
Waters Corporation (NYSE:WAT) today announced it is expanding its waters_connect™ informatics software platform to support customers analyzing food and environmental samples with Waters’ tandem quadrupole mass spectrometers. The new MS Quan ™ application for waters_connect allows laboratories screening large numbers of samples, or those who may be quantifying hundreds of small molecule components and contaminants in a single run, a more efficient means of processing and reviewing data and identifying batch-to-batch variations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005625/en/
For laboratories using Waters™ Xevo™ mass spectrometers, the MS Quan app quickly and accurately converts measurement data on compounds into meaningful results in a traceable, compliant, and secure manner. Featuring a web-based user interface, the MS Quan app includes an Exception Focused Review (XFR) feature that can help cut data review time by up to 50% by allowing users to focus on only those results that fall outside the user-determined ruleset.
“The waters_connect platform provides a backbone for the connected lab of the future where data is no longer siloed but can be securely shared among a community of connected scientists using apps that talk to each other,” said Jon Pratt, Senior Vice President, Waters Corporation. “MS Quan is a great example of the new applications and quality improvements we are bringing to our customers via waters_connect and its platform architecture designed for data integrity, compliance, security and accessibility.”
Several scientists from Primoris (Zwijnaarde, Belgium), a global contract laboratory, participated in the beta testing of the MS Quan software application. Primoris measures pesticide residues and contaminants in food and animal feed as well as analyzing food additives, supplements, and essential oils.
“We’ve used MassLynx and TargetLynx from Waters for a very long time so we knew from the beginning the potential that this new app will offer," said Janne Dombrecht, Analysis Lead, Primoris Belgium. “The final product is exactly what we were looking for. Our close relationship with Waters and being able to test this product to make sure it is optimal for our methods has been a win-win situation. We’re excited to roll it out across Primoris!”
The waters_connect for quantitation workflow and MS Quan app are now available worldwide as an upgrade for select Waters’ tandem quadrupole mass spectrometers.i
Additional Resources
- Learn more about the MS Quan app on waters_connect
- Read the blog: “Helping Laboratories Embrace New Era of Efficiency”
- Download the white paper: “The Benefits of waters_connect MRM Processing Application, MS Quan”
About Waters Corporation (www.waters.com )
Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,400 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters, MS Quan, Xevo, MassLynx, TargetLynx, and waters_connect are trademarks of Waters Corporation. Primoris is a trademark of Primoris Belgium.
____________________________
i
At this time the MS Quan app is for small molecule quantification studies and compatible with Waters Xevo TQ-XS, a Waters Xevo TQ-S micro and Waters TQ-S cronos tandem quadrupole mass spectrometers with either an ACQUITY I-Class, H-Class System or ACQUITY Premier System front-end. Additionally, waters_connect software is currently available as an “on-premise” only workstation product.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005625/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release
A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
